MedTrace Logo

Retrospective Data Collection: Post Study Treatment Anticancer Therapy From IMELDA MO22223

NCT02383576 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 185

Last updated 2018-04-13

Study results available
· View outcomes & findings →

Summary

This study aims to understand better the effective results from the IMELDA MO22223 P-trial (NCT00929240) and see if the anti-cancer therapies given during its follow-up time after study treatments were terminated possibly had an effect on efficacy results.

Conditions

Interventions

OTHER

No Intervention

No intervention administered in this study.

Sponsors & Collaborators

Principal Investigators

  • Reference Study ID Number: MO29587 www.roche.com/about_rouche/roche_worldwide.htm · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-01-22
Completion
2016-01-22

Countries

  • Brazil
  • France
  • India
  • Italy
  • Spain
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02383576 on ClinicalTrials.gov